Results 191 to 200 of about 31,287 (242)

A Rare Case of Cutaneous Crystal‐Storing Histiocytosis With Kappa Light Chain Restriction and Unusual BCL6 Expression

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Crystal‐storing histiocytosis (CSH) is a rare histopathologic phenomenon characterized by the accumulation of crystalline material within histiocytes, most often associated with lymphoplasmacytic or plasma cell neoplasms. Cutaneous involvement is uncommon and may present diagnostic challenges.
Liangli Wang, Jonathan L. Curry, Julia Dai, Daniel H. Wang, Paolo Strati, Melody R. Becnel, Leomar Y. Ballester, Carlos A. Torres‐Cabala, Phyu P. Aung   +8 more
wiley   +1 more source

Real‐world comparison of peripheral neuropathy and treatment delivery between Pola‐R‐CHP and R‐CHOP in DLBCL

British Journal of Haematology, EarlyView.
Nobuhiko Nakamura, Koichi Ohata, Tomohiro Aizaki, Yuto Kaneda, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Serika Banno Matsuoka, Shiori Hishida Sadaka, Akio Suzuki, Nobuhiro Kanemura, Masahito Shimizu   +11 more
wiley   +1 more source

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler, Simon Lüdtke, Lena Dietze, Marie Schiffmann, Dominik Straube, Jan Ehrchen   +5 more
wiley   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara, Katlyn G. McKay, Harold N. Lovvorn III, Joseph C. Fusco   +3 more
wiley   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation

European Journal of Haematology, EarlyView.
ABSTRACT T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with
Atte Karhu, Sara Aronen, Aino Rönkä, Kaisa Sunela, Tuula Klaavuniemi, Annikki Aromaa‐Häyhä, Milla Kuusisto, Otto Jokelainen, Jan Böhm, Kristiina Vuolukka, Ulla‐Mari Arkko, Samuli Vaittinen, Minna Harmanen, Juha P. Väyrynen, Hanne Kuitunen, Sonja Nousiainen, Joonas Kuitunen, Juho Kangas, Eetu Pellonperä, Henri Kurttila, Miko Pietilä, Jaakko Tirkkonen, Outi Kuittinen   +22 more
wiley   +1 more source

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source